These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33758482)

  • 1. Vulnerabilities and resilience in insurance investing: studying the COVID-19 pandemic.
    Liedtke PM
    Geneva Pap Risk Insur Issues Pract; 2021; 46(2):266-280. PubMed ID: 33758482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Sudden Public Health Events on the Insurance Companies' Investment Returns: Based on the Investors' Sentiment Perspective.
    Shang Y; Qian F; Gao N; Yang Q; Guo Y; Sun Y
    Front Public Health; 2022; 10():810515. PubMed ID: 35242732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Well-Designed Implement for Promoting Population Health and Property
    Liu Z; Zhao L; Wu YC; Chuang MC; Wang MC
    Front Public Health; 2021; 9():766003. PubMed ID: 35174131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insurers' intervention, separation of two rights and firm's technology innovation.
    Xu B; Hao F
    Front Public Health; 2023; 11():1181219. PubMed ID: 37124801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A return to insurance companies' dominance in the group health market?
    Cerone JR
    J Med Pract Manage; 1989; 4(4):235-41. PubMed ID: 10293705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suspension of insurers' dividends as a response to the COVID-19 crisis: evidence from the European insurance equity market.
    Jakubik P; Teleu S
    Geneva Pap Risk Insur Issues Pract; 2022; 47(4):785-816. PubMed ID: 34629828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capped borrower credit risk and insurer hedging during the COVID-19 outbreak.
    Chen S; Yang Y; Lin JH
    Financ Res Lett; 2020 Oct; 36():101744. PubMed ID: 32905078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Big Five Health Insurers' Membership And Revenue Trends: Implications For Public Policy.
    Schoen C; Collins SR
    Health Aff (Millwood); 2017 Dec; 36(12):2185-2194. PubMed ID: 29200327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonprofit health insurers: the story Wall Street doesn't tell.
    Johnson SR
    Inquiry; 2003; 40(4):318-22. PubMed ID: 15055832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price setting in the Brazilian private health insurance sector.
    Andrade MV; Marinho C; Nunes L; Colares F
    Int J Health Econ Manag; 2024 Mar; 24(1):57-80. PubMed ID: 37691041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much cash does your company need?
    Passov R
    Harv Bus Rev; 2003 Nov; 81(11):119-22, 124-6, 128, 140. PubMed ID: 14619157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual insurance: health insurers try to tap potential market growth.
    November EA; Cohen GR; Ginsburg PB; Quinn BC
    Res Brief; 2009 Nov; (14):1-8. PubMed ID: 19899193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquidity, Technological Opportunities, and the Stage Distribution of Venture Capital Investments.
    Lahr H; Mina A
    Financ Manage; 2014 Jun; 43(2):291-325. PubMed ID: 26166906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covid-19: implications for insurer risk management and the insurability of pandemic risk.
    Richter A; Wilson TC
    Geneva Risk Insur Rev; 2020; 45(2):171-199. PubMed ID: 32982612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing equity and policyholder protection: Assessing insurer's interests in green lending under cap-and-trade regulations.
    Chen S; Zhao Y; Chiu SC; Wu J; Lin JH
    PLoS One; 2023; 18(11):e0293975. PubMed ID: 37930970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risky business: Data on trading results for UK general insurance firms during and after the global financial crisis.
    Mafimisebi OP
    Data Brief; 2018 Dec; 21():2384-2389. PubMed ID: 30555878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Canada Pension Plan's experience with investing its portfolio in equities.
    Sarney M; Preneta AM
    Soc Secur Bull; 2001-2002; 64(2):46-56. PubMed ID: 12428509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capital issuances and premium growth in the property-liability insurance industry: evidence from the financial crisis and COVID-19 recession.
    Berry-Stölzle TR; Esson MI
    Geneva Pap Risk Insur Issues Pract; 2023 Jan; ():1-25. PubMed ID: 36743395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.